Restoring Brain Health

amyloid precursor protein alzheimer's

Stopping Toxic Cascade in Neurodegeneration

Neurodegeneration involves the gradual breakdown and loss of neuron function, a hallmark of diseases like Alzheimer's and Parkinson's. In a healthy state, nerve cells efficiently receive, process, and transmit signals through their axons, the long fibers that connect via synapses. However, when these cells are damaged or stressed, they begin producing neurotoxic proteins that disrupt this communication. This leads to impaired axonal transport and a slowdown of information flow. Ultimately, the immune system targets these compromised cells, leading to their death—a process known as the toxic cascade. By targeting these harmful proteins, we can interrupt this cascade and protect nerve cells from degeneration.

new alzheimer's treatment

Toxic Cascade

NEUROTOXIC PROTEINS IMPAIR AXONAL TRANSPORT
AND CAUSE A TOXIC CASCADE

HIGH LEVELS OF NEUROTOXIC PROTEINS
IMPAIRED AXONAL TRANSPORT
SLOWER SYNAPTIC TRANSMISSION
INCREASED INFLAMMATION
DEATH OF NERVE CELLS
LOSS OF COGNITIVE AND MOTOR FUNCTION

Our Solution

BUNTANETAP IMPROVES AXONAL TRANSPORT AND
IMPEDES THE TOXIC CASCADE

LOW LEVELS OF NEUROTOXIC PROTEINS
IMPROVED AXONAL TRANSPORT
FASTER SYNAPTIC TRANSMISSION
REDUCED INFLAMMATION
HEALTHY NERVE CELLS
IMPROVED COGNITIVE AND MOTOR FUNCTION

Buntanetap: A Next-Generation Approach to Neurodegenerative Disease

home 2 imageservices imagehome 2 imageservices image

Buntanetap (previously known as Posiphen) is a translational inhibitor of neurotoxic aggregating proteins. Different from monoclonal antibody therapies, buntanetap is an orally available small molecule with a unique mechanism of action that allows it to inhibit multiple neurotoxic proteins at once, including amyloid precursor proteins (APP), tau, αSYN, and TDP-43. Recent research has shown that multiple neurotoxic proteins are at play in all neurodegenerative diseases, and attacking only one protein has minimal effect.

pathology of alzheimers diseasealzheimer's disease pathologylatest alzheimer's drug
alzheimer's disease clinical trials and drug development